Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
NEW YORK, Feb. 17, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased GW Pharmaceuticals plc (Nasdaq:GWPH) securities between December 4, 2014 and January 8, 2016.
Click here to learn about the case: http://docs.wongesq.com/GWPH-Info-Request-Form-1080. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company lacked effective internal financial controls; (ii) the Company lacked effective controls over completeness and valuation of clinical trial accruals; and (iii) as a result of the foregoing, Defendants’ statements about GW Pharmaceuticals’ business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
In its 2015 Annual Report, GW Pharmaceuticals disclosed the discovery of a material weakness in its internal control over financial reporting for the year ended September 30, 2015. The Company noted that “management does not have sufficiently precise controls to evaluate the completeness and accuracy of the calculation of clinical trial accruals due to the incorrect allocation of expenditure to clinical studies.” On this news, GW Pharmaceuticals stock fell $3.55, or nearly 6%, to close at $56.31 per share on January 11, 2016.
If you suffered a loss in GW Pharmaceuticals you have until March 21, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/GWPH-Info-Request-Form-1080.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigation involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
